2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other
1
Classical hematology
1
Conditions
Venous Thromboembolism
16
Venous Thrombosis
12
Pulmonary Embolism
11
Neoplasms
10
Thrombosis
4
Thromboembolism
4
Pancreatic Neoplasms
4
Lung Neoplasms
4
Multiple Myeloma
3
Neoplasm Metastasis
2
Lymphoma
2
Hemorrhage
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Cervical Neoplasms
1
Thrombophilia
1
Thrombocytopenia
1
Thrombocythemia, Essential
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precancerous Conditions
1
Ovarian Neoplasms
1
Obesity
1
Neoplasms, Plasma Cell
1
Interventions
Exercise
25
Metformin
23
Tirzepatide
9
Resistance Training
8
Nutrition Assessment
8
Methods
8
Diet Therapy
8
Diet
8
Counseling
8
Surveys and Questionnaires
6
Early Intervention, Educational
6
Caloric Restriction
6
semaglutide
5
Liraglutide
5
Exenatide
5
Diet, Mediterranean
5
Blood Specimen Collection
5
Educational Status
4
Docosahexaenoic Acids
4
Bariatric Surgery
4
exemestane
3
Vitamin D
3
Therapeutics
3
Tamoxifen
3
Sugars
3
Standard of Care
3
Observation
3
Naltrexone
3
Letrozole
3
Dexamethasone
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Obesity
×
Dalteparin
×
Clear all
NCT03297359
2024-01-23
WAVe
Ottawa Hospital Research Institute
Phase 2
Terminated
92 enrolled